HTA bodies evaluate the clinical effectiveness, safety, and cost-effectiveness of medical technologies to inform coverage and pricing - NICE (UK), HAS (France), G-BA/IQWiG (Germany), CADTH (Canada), and the new EU Joint Clinical Assessment (JCA). HTA reviews usually look at clinical evidence against a comparator, cost-effectiveness and budget impact, and sometimes ethical and organizational issues. Processes differ by country: some focus on clinical benefit, others on cost per QALY. Early scientific advice from HTA bodies helps companies design trials that both regulators and payers accept.

Why it matters

Outside the U.S., HTA decisions often gate market access. EU JCA (effective 2025) creates a single clinical assessment across member states for high-risk devices and IVDs.

Common pitfalls

•Misunderstanding HTA as a regulatory approval process, rather than a reimbursement and market access gate.
•Failing to consider HTA requirements early in product development, leading to late-stage data collection challenges.
•Underestimating the data requirements for HTA submissions, which often go beyond basic regulatory clinical evidence.
•Assuming that a device approved in one jurisdiction will automatically receive favorable HTA outcomes in others.
•Neglecting to engage with HTA bodies or experts during the clinical development planning phase.

Sources

INAHTA · INAHTA
Health technology evaluation · NICE

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.